A New Era of Unified Adverse Event Monitoring Postmarketing safety surveillance remains a cornerstone of regulatory science, as clinical trials may not detect rare or long-term adverse events due to limited sample sizes, controlled conditions, and follow-up duration. The U.S. FDA relies on adverse event reporting systems to monitor the real-world safety of regulated products, [...]